| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787641 | Journal of Thoracic Oncology | 2018 | 32 Pages |
Abstract
As adjuvant chemotherapy, paclitaxel plus carboplatin was no better than UFT in terms of survival among patients with stage IB to IIIA NSCLC tumors who underwent complete resection (UMIN000000810).
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Shinichi MD, PhD, Norihito MD, PhD, Hiroshige MD, PhD, Masao MD, PhD, Motohiro MD, PhD, Hirohito MD, Shinsuke MD, PhD, Naoki MD, PhD, Morihito MD, PhD, Junichi MD, PhD, FACS, Motoi MD, PhD, Junichi MD, PhD, Shinichiro MD, PhD, Katsuyuki MD, PhD,